Company: PETVW
Filing Date: 2025-07-10
Form Type: 10-K
Source: 0001641172-25-018617
Chunk: 132

Company: PetVivo Holdings, Inc.
Filing Date: 2025-07-10
Form: 10-K
Item: Item 1A
Chunk 132
---
An
investment in our common stock and warrants involves a high degree of risk. You should carefully consider the following described risks
together with all other information included in this prospectus before making an investment decision with regard to this offering. If
one or more of the following risks occurs, our business, financial condition, and results of operations could be materially harmed, which
most likely would result in a decline in the trading price of our common stock and warrants and investors losing part or even all of
their investment.

Risks
Relating to Our Financial Condition

The
Company’s failure to meet the continued listing requirements of The Nasdaq Capital Market has resulted in a delisting of its securities.

Our
common stock and warrants were delisted for trading on Nasdaq and on July 26, 2024, we received approval for trading on the OTCQB market.

We
have incurred substantial losses to date and could continue to incur such losses.

We
have incurred substantial losses since commencing our current business. For the year ended March 31, 2025, we lost approximately $8.0
million without obtaining any significant commercial revenues and had an accumulated deficit of approximately $90.8 million. In order
to achieve and sustain future revenues, we must succeed in our current efforts to commercialize Spryng® for treatment
of dogs and horses suffering from osteoarthritis. That will require us to produce our products effectively in commercial quantities,
establish adequate sales and marketing systems, conduct clinical trials and tests which show the safety and efficacy of Spryng®
in dogs and horses and gain significant support from veterinarians in the use of our products. We expect to continue to incur losses
until such time, if ever, as we succeed in significantly increasing our revenues and cash flow beyond what is necessary to fund our ongoing
operations and pay our obligations as they become due. We may never generate revenues sufficient to become profitable or to sustain profitability.

14

If
we are unable to obtain sufficient funding, we may have to reduce materially or even discontinue our business.

As
of March 31, 2025, we have cash or cash equivalents of approximately $228,000. We anticipate that we will be adequate to satisfy operational
and capital requirements for the next one (1) month. If we are unable to realize substantial revenues in the near future, we will need
to seek additional financing beyond this three-month period to continue our operations. We also most likely will require additional financing
to develop